Hiperdipina (Nitrendipine)

Hiperdipina is prescribed primarily for the treatment of hypertension and may be incorporated into a comprehensive blood‑pressure management plan, either as monotherapy or in combination with other antihypertensive agents.

• Essential (primary) hypertension, where elevated blood pressure is not attributable to a secondary cause.
• Secondary hypertension that responds inadequately to first‑line agents, such as ACE inhibitors or thiazide diuretics.
• Hypertensive patients who require additional vasodilation due to high peripheral resistance.
• Patients with hypertension and co‑existing coronary artery disease where vasodilatory therapy is appropriate.
• Elderly individuals who need a once‑daily oral calcium‑channel blocker with a favorable dosing schedule.

• Nitrendipine selectively blocks L‑type calcium channels located on vascular smooth‑muscle cells. By inhibiting calcium influx during depolarization, it prevents contraction of arterial smooth muscle, leading to vasodilation of peripheral resistance vessels. The resulting decrease in systemic vascular resistance lowers arterial pressure without markedly affecting cardiac contractility or heart rate. The drug’s high affinity for the vascular isoform of the channel provides a relatively selective effect on peripheral arteries, while sparing the myocardium and conduction system.

Like other calcium‑channel blockers, nitrendipine can cause a range of adverse reactions, most of which are mild and transient, and typically resolve with continued therapy or dose adjustment. Patients should report any unexpected or severe symptoms to their healthcare provider promptly.

Common

• Headache, often occurring during the initial treatment period.
• Flushing or a sensation of warmth caused by peripheral vasodilation.
• Dizziness or light‑headedness, especially on standing (orthostatic effect).
• Mild peripheral edema, typically swelling of the ankles or lower legs.

Serious

• Marked hypotension leading to fainting or falls.
• Significant tachycardia or palpitations that may require medical evaluation.
• Severe allergic reactions, including rash, pruritus, or angio‑edema.
• Hepatic dysfunction manifested by jaundice or elevated liver enzymes.

When prescribing nitrendipine, clinicians consider several precautionary factors to ensure safe use and to minimize risk.

• Use with caution in patients with severe liver impairment.
• Monitor blood pressure regularly, especially after dose initiation or changes.
• Avoid abrupt discontinuation, which may cause rebound hypertension.
• Use cautiously in patients with a history of heart failure.
• Assess for potential drug interactions before adding other antihypertensives.
• Consider dose adjustment in elderly patients due to altered pharmacokinetics.

Nitrendipine may alter the plasma concentrations or effects of several concomitant medicines; awareness of these interactions helps optimize therapy.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) that can markedly increase nitrendipine levels.
• Grapefruit juice, which inhibits intestinal CYP3A4 and may raise drug exposure.
• Concurrent use with other potent vasodilators (e.g., nitroglycerin) that can precipitate severe hypotension.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem) that may produce additive cardiac effects.

Use with caution

• Beta‑blockers, as combined therapy may require blood pressure monitoring.
• Diuretics, especially thiazides, which can enhance antihypertensive effect and electrolyte shifts.
• ACE inhibitors or ARBs, where additive blood pressure lowering may occur.
• Antidepressants that affect CYP3A4 (e.g., fluoxetine) may modestly increase nitrendipine exposure.